Similar articles

• Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.

  Naito T, Shiraishi H, Fujiwara Y. Naito T, et al. Jpn J Clin Oncol. 2021 Jan 1;51(1):37-44. doi: 10.1093/jjco/hyaa192. Jpn J Clin Oncol. 2021. PMID: 33147606 Review.
• Lorlatinib in the treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.

  Stinchcombe TE. Stinchcombe TE. Ann Oncol. 2021 May;32(5):587-589. doi: 10.1016/j.annonc.2021.03.002. Epub 2021 Mar 17. Ann Oncol. 2021. PMID: 33741444 No abstract available.
• ASCEND-8 pharmacokinetic, safety, and efficacy data for ceritinib 450 mg with food in patients with anaplastic lymphoma kinase-positive non-small cell lung Cancer: A clinical perspective.

  Otoukesh S, Sanchez T, Mirshahidi S, Wallace D, Mirshahidi H. Otoukesh S, et al. Cancer Treat Res Commun. 2019;20:100149. doi: 10.1016/j.ctarc.2019.100149. Epub 2019 May 1. Cancer Treat Res Commun. 2019. PMID: 31075537 Clinical Trial.
• Screening for anaplastic lymphoma kinase (ALK) gene rearrangements in non-small-cell lung cancer in New Zealand.

  McKeage MJ, Tin Tin S, Khwaounjoo P, Sheath K, Dixon-McIver A, Ng D, Sullivan R, Cameron L, Shepherd P, Laking GR, Kingston N, Strauss M, Lewis C, Elwood M, Love DR. McKeage MJ, et al. Intern Med J. 2020 Jun;50(6):716-725. doi: 10.1111/imj.14435. Intern Med J. 2020. PMID: 31318119
• The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC).

  Golding B, Luu A, Jones R, Viloria-Petit AM. Golding B, et al. Mol Cancer. 2018 Feb 19;17(1):52. doi: 10.1186/s12943-018-0810-4. Mol Cancer. 2018. PMID: 29455675 Free PMC article. Review.